Could a diabetes drug ease heart failure in rare amyloid disease?
NCT ID NCT05795400
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug dapagliflozin (a diabetes medicine) in 50 adults with heart failure due to amyloid cardiomyopathy, a rare condition where abnormal proteins stiffen the heart. Researchers measured changes in quality of life, walking distance, and heart stress markers over time. The goal was to see if the drug can safely ease symptoms and improve daily function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOID CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Moscow, 121552, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could continuing a common heart drug before surgery save lives?
- Can shedding pounds reboot the Heart's exercise engine?
- Can a daily pill keep a rare heart disease in check for the long haul?
- Could a natural chemical be the key to safer heart failure treatment?
- Can a Breathing-Synchronized pacemaker boost heart function after bypass?
- Can 3D heart scans outperform standard ultrasound in predicting risk?